These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 31664708)
21. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Akturk HK; Rewers A; Garg SK Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497 [TBL] [Abstract][Full Text] [Related]
22. Clinical implication of SGLT2 inhibitors in type 2 diabetes. Kim GW; Chung SH Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857 [TBL] [Abstract][Full Text] [Related]
23. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Scheen AJ Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice. Bayona Cebada A; Nattero-Chávez L; Alonso Díaz S; Escobar-Morreale HF; Luque-Ramírez M Diabetes Technol Ther; 2020 Mar; 22(3):208-215. PubMed ID: 31644310 [No Abstract] [Full Text] [Related]
25. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426 [TBL] [Abstract][Full Text] [Related]
27. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders. Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624 [TBL] [Abstract][Full Text] [Related]
28. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. Garnock-Jones KP Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222 [TBL] [Abstract][Full Text] [Related]
29. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432 [TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus. Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772 [TBL] [Abstract][Full Text] [Related]
32. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Demaris KM; White JR Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. Araki E; Watada H; Uchigata Y; Tomonaga O; Fujii H; Ohashi H; Okabe T; Asano M; Thoren F; Kim H; Yajima T; Langkilde AM Diabetes Obes Metab; 2020 Apr; 22(4):540-548. PubMed ID: 31742898 [TBL] [Abstract][Full Text] [Related]
34. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. McGurnaghan SJ; Brierley L; Caparrotta TM; McKeigue PM; Blackbourn LAK; Wild SH; Leese GP; McCrimmon RJ; McKnight JA; Pearson ER; Petrie JR; Sattar N; Colhoun HM; Diabetologia; 2019 Apr; 62(4):621-632. PubMed ID: 30631892 [TBL] [Abstract][Full Text] [Related]
35. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895 [TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin: a review on efficacy, clinical effectiveness and safety. Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205 [TBL] [Abstract][Full Text] [Related]
37. SGLT inhibitor adjunct therapy in type 1 diabetes. McCrimmon RJ; Henry RR Diabetologia; 2018 Oct; 61(10):2126-2133. PubMed ID: 30132030 [TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Mathieu C; Rudofsky G; Phillip M; Araki E; Lind M; Arya N; Thorén F; Scheerer MF; Iqbal N; Dandona P Diabetes Obes Metab; 2020 Sep; 22(9):1516-1526. PubMed ID: 32311204 [TBL] [Abstract][Full Text] [Related]
39. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]